Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Sees Large Increase in Short Interest

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) saw a significant growth in short interest in August. As of August 14th, there was short interest totaling 51,809 shares, a growth of 205.1% from the July 30th total of 16,980 shares. Based on an average daily volume of 11,844,452 shares, the short-interest ratio is currently 0.0 days. Approximately 1.2% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on BJDX. Weiss Ratings restated a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Wednesday, June 24th. Wall Street Zen upgraded shares of Bluejay Diagnostics from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Bluejay Diagnostics has a consensus rating of “Sell”.

Bluejay Diagnostics Stock Up 1.8%

Shares of NASDAQ:BJDX traded up $0.02 during midday trading on Thursday, hitting $0.91. The stock had a trading volume of 144,313 shares, compared to its average volume of 2,361,801. The company has a market cap of $4.07 million, a P/E ratio of -0.13 and a beta of 0.89. The business’s 50-day simple moving average is $1.48 and its 200-day simple moving average is $2.06. Bluejay Diagnostics has a 12 month low of $0.83 and a 12 month high of $16.68.

Bluejay Diagnostics (NASDAQ:BJDX) last issued its earnings results on Wednesday, August 12th. The company reported ($1.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3,520.00) by $3,518.88.

Insider Buying and Selling

In other news, major shareholder Financial Lp Hrt bought 64,047 shares of the stock in a transaction dated Thursday, July 9th. The stock was bought at an average cost of $1.51 per share, with a total value of $96,710.97. Following the purchase, the insider owned 126,993 shares of the company’s stock, valued at approximately $191,759.43. This represents a 101.75% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Bluejay Diagnostics

An institutional investor recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC bought a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned approximately 9.15% of Bluejay Diagnostics as of its most recent filing with the Securities & Exchange Commission. 18.47% of the stock is currently owned by institutional investors.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.